Patents by Inventor Anne-Sophie Rebstock
Anne-Sophie Rebstock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210230284Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: April 8, 2021Publication date: July 29, 2021Applicant: Bayer Pharma AktiengesellschaftInventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH
-
Patent number: 11071788Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: June 20, 2016Date of Patent: July 27, 2021Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Sandra Berndt, Uwe Gritzan, Jenny Fitting, Beatrix Stelte-Ludwig, Patrick Jones, Christoph Mahlert, Christian Votsmeier, Dorian Schönfeld, Mark Trautwein, Ernst Weber, Nikolaus Pawlowski, Simone Greven, Julian Marius Glück, Stefanie Hammer, Lisa Dietz, Stephan Märsch
-
Publication number: 20210147371Abstract: The present disclosure relates to oxadiazoline derivatives that may be used as fungicides.Type: ApplicationFiled: April 9, 2019Publication date: May 20, 2021Inventors: Andreas GOERTZ, Anne-Sophie REBSTOCK, Sebastien NAUD, Mathieu GOURGUES, Emmanuelle HILT, Philippe DESBORDES, Jeremy DUFOUR, Sophie DUCERF, Stephane BRUNET, Vincent THOMAS
-
Patent number: 11001636Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD 123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: June 8, 2017Date of Patent: May 11, 2021Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Beatrix Stelte-Ludwig, Dennis Kirchhoff, Christoph Mahlert, Simone Greven, Stephan Märsch
-
Patent number: 10973923Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: June 20, 2016Date of Patent: April 13, 2021Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Yolanda Cancho Grande, Beatrix Stelte-Ludwig, Anette Sommer, Christoph Mahlert, Anne-Sophie Rebstock, Simone Greven, Nils Griebenow, Jan Tebbe, Oliver Kensch
-
Publication number: 20210009541Abstract: The present invention relates to oxadiazole derivatives thereof that may be used as fungicides.Type: ApplicationFiled: February 11, 2019Publication date: January 14, 2021Inventors: Stephane BRUNET, Philippe DESBORDES, Sophie DUCERF, Jeremy DUFOUR, Andreas GOERTZ, Mathieu GOURGUES, Emmanuelle HILT, Sebastien NAUD, Anne-Sophie REBSTOCK, Vincent THOMAS, Aurelia VERNAY, Francois VILLALBA
-
Publication number: 20210009575Abstract: The present disclosure relates to the use of hydroxyisoxazolines and derivatives thereof as fungicide. It also relates to new hydroxyisoxazolines derivatives, their use as fungicide and compositions comprising thereof.Type: ApplicationFiled: December 21, 2019Publication date: January 14, 2021Inventors: Anne-Sophie REBSTOCK, Sebastien NAUD, Stephane BRUNET, Mathieu GOURGUES, Francois Michel VILLALBA, Aurelia VERNAY, Birgit KUHN, Andreas GOERTZ, Philippe DESBORDES, Jeremy DUFOUR, Emmanuelle HILT, Sophie DUCERF
-
Publication number: 20210007359Abstract: The present invention relates to heterocyclylaminophenyloxadiazole and derivatives thereof that may be used and as fungicides.Type: ApplicationFiled: December 21, 2018Publication date: January 14, 2021Inventors: Anne-Sophie REBSTOCK, Sebastien NAUD, Stephane BRUNET, Mathieu GOURGUES, Harald JAKOBI, Andreas GOERTZ, Emmanuelle HILT, Sophie DUCERF
-
Patent number: 10744205Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: June 20, 2016Date of Patent: August 18, 2020Assignee: Bayer Pharma AktiengesellschaftInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Beatrix Stelte-Ludwig, Christoph Mahlert, Simone Greven, Stephan Märsch, Dennis Kirchhoff
-
Publication number: 20200138970Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: June 20, 2016Publication date: May 7, 2020Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Sandra BERNDT, Uwe GRITZAN, Jenny FITTING, Beatrix STELTE-LUDWIG, Patrick JONES, Christoph MAHLERT, Christian VOTSMEIER, Dorian SCHÖNFELD, Mark TRAUTWEIN, Ernst WEBER, Nikolaus PAWLOWSKI, Simone GREVEN, Julian Marius GLÜCK, Stefanie HAMMER, Lisa DIETZ, Stephan MÄRSCH
-
Patent number: 10519154Abstract: The present application relates to novel 7-substituted 1-pyridylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.Type: GrantFiled: July 4, 2017Date of Patent: December 31, 2019Assignees: Bayer Pharma Aktiengesellschaft, Bayer AktiengesellschaftInventors: Henrik Teller, Melissa Boultadakis Arapinis, Alexandros Vakalopoulos, Anne-Sophie Rebstock, Alexander Straub, Hanna Tinel, Markus Brechmann, Matthias Beat Wittwer, Maximillian Andreas Kullmann, Klaus Münter, Thomas Mondritzki, Tobias Marquardt
-
Publication number: 20190365916Abstract: Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.Type: ApplicationFiled: December 18, 2017Publication date: December 5, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Sandra BERNDT, Lisa DIETZ, Stephan MÄRSCH, Stefanie HAMMER
-
Publication number: 20190367516Abstract: The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.Type: ApplicationFiled: August 13, 2019Publication date: December 5, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Henrik TELLER, Alexander STRAUB, Markus BRECHMANN, Thomas MÜLLER, Mark MEININGHAUS, Katrin NOWAK-REPPEL, Hanna TINEL, Klaus MÜNTER, Daniela FLIEGNER, Thomas MONDRITZKI, Melissa BOULTADAKIS ARAPINIS, Tobias MARQUARDT, Alexandros VAKALOPOULOS, Anne-Sophie REBSTOCK, Matthias Beat WITTWER
-
Patent number: 10485880Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: December 10, 2015Date of Patent: November 26, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Hans-Georg Lerchen, Sven Wittrock, Yolanda Cancho Grande, Beatrix Stelte-Ludwig, Anette Sommer, Sandra Berndt, Christoph Mahlert, Anne-Sophie Rebstock, Carsten Terjung, Simone Greven
-
Publication number: 20190351066Abstract: The invention relates to novel prodrugs or conjugates of the general formula (Ia) in which La, n, R and D have the definitions given in the description and which have a structural motif reduced to an asparagine derivative as cleavage site for tumour-associated proteases such as legumain, in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are released by legumain cleavage, and to the use of these prodrugs or conjugates for treatment and/or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and/or prevention of diseases, especially of hyperproliferative and/or angiogenic disorders, for example cancers. Reduction of the legumain-cleavable substrate peptide sequence to an asparagine derivative as structural motif, as a result of slowed legumain cleavage, achieves an increase in stability in the lysosomes of healthy organs while simultaneously maintaining the high anti-tumour effect.Type: ApplicationFiled: December 18, 2017Publication date: November 21, 2019Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Leo MARX, Sarah Anna Liesa JOHANNES, Beatrix STELTE-LUDWIG, Lisa DIETZ, Hannah JOERISSEN, Christoph MAHLERT, Simone GREVEN, Anette SOMMER
-
Publication number: 20190330357Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD 123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: June 8, 2017Publication date: October 31, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH
-
Publication number: 20190328897Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.Type: ApplicationFiled: December 14, 2017Publication date: October 31, 2019Applicants: Bayer Pharma Aktiengesellschaft, Bayer AktiengesellschaftInventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Lisa DIETZ, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Sandra BERNDT, Anette SOMMER, Stefanie HAMMER
-
Patent number: 10435403Abstract: The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.Type: GrantFiled: June 6, 2016Date of Patent: October 8, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Henrik Teller, Alexander Straub, Markus Brechmann, Thomas Müller, Mark Meininghaus, Katrin Nowak-Reppel, Hanna Tinel, Klaus Münter, Daniela Fliegner, Thomas Mondritzki, Melissa Boultadakis Arapinis, Tobias Marquardt, Alexandros Vakalopoulos, Anne-Sophie Rebstock, Matthias Beat Wittwer
-
Publication number: 20190262463Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: June 20, 2016Publication date: August 29, 2019Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg LERCHEN, Yolanda CANCHO GRANDE, Beatrix STELTE-LUDWIG, Anette SOMMER, Christoph MAHLERT, Anne-Sophie REBSTOCK, Simone GREVEN, Nils GRIEBENOW, Jan TEBBE, Oliver KENSCH
-
Publication number: 20190241562Abstract: The present application relates to novel 7-substituted 1-pyridylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.Type: ApplicationFiled: July 4, 2017Publication date: August 8, 2019Applicants: Bayer Pharma Aktiengesellschaft, Bayer AktiengesellschaftInventors: Henrik TELLER, Melissa BOULTADAKIS ARAPINIS, Alexandros VAKALOPOULOS, Anne-Sophie REBSTOCK, Alexander STRAUB, Hanna TINEL, Markus BRECHMANN, Matthias Beat WITTWER, Maximillian Andreas KULLMANN, Klaus MÜNTER, Thomas MONDRITZKI, Tobias MARQUARDT